OrganonOGN +0.22%73 ROE % is 70.57% as of Mar. 2026, which is 54% above its 10-year median of 45.74. GuruFocus rates OGN with a GF Score™ of 73/100 and a GF Value™ of $14.55 (Fairly Valued). The stock has 9 warning signs investors should review. Among 936 Drug Manufacturers companies, Organon ranks better than 94.34% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Organon's annualized net income for the quarter that ended in Mar. 2026 was $584 Mil. Organon's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $828 Mil. Therefore, Organon's annualized ROE % for the quarter that ended in Mar. 2026 was 70.57%.
The historical rank and industry rank for Organon's ROE % or its related term are showing as below:
OGN'
s ROE % Range Over the Past 10 Years
Min: 30.56 Med: 45.74 Max: 429.85
Current: 32.06
During the past 8 years, Organon's highest ROE % was 429.85%. The lowest was 30.56%. And the median was 45.74%.
OGN's ROE % is ranked better than 94.34% of 936
companies
in the Drug Manufacturers industry
Industry Median: 5.865
vs OGN: 32.06
Organon (NYSE:OGN) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Organon ROE % Related Terms
Organon ROE % Historical Data
* Premium members only.
The historical data trend for Organon's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Organon's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organon ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organon's ROE % distribution charts can be found below:
* The bar in red indicates where Organon's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Organon (OGN) has a ROE % of 70.57% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Organon and its competitors. This is 54% above median its historical median of 45.74. Over the past decade, Organon's ROE % has ranged from 30.56 to 429.85. According to the industry distribution chart, Organon ranks #53 out of 936 companies in the Drug Manufacturers industry, placing it in the top 5.7%.
Is Organon's ROE % too high?
Organon's current ROE % of 70.57% is 54% above median its 10-year median of 45.74. Over the past 10 years, this metric has ranged from a low of 30.56 to a high of 429.85. The Drug Manufacturers industry median ROE % is 5.87. Organon's value of 70.57% is 1103.2% above this industry median. Based on the distribution chart, Organon ranks #53 out of 936 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Organon has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Organon's ROE % compare to AMRN and SCLX?
According to the Drug Manufacturers industry distribution chart, Organon ranks #53 out of 936 companies for ROE %. This places Organon in the top 6% of its industry — outperforming the majority of peers. The industry median ROE % is 5.87. Organon's value of 70.57% is 1103.2% above this benchmark. Historically, Organon's own ROE % has ranged from 30.56 to 429.85 over the past decade. While the company's 10-year median is 45.74 vs. the industry median of 5.87, Organon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organon's current ROE % of 70.57% is 1103.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Organon and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organon's current ROE % is 70.57%, which is 54% above median its own 10-year median of 45.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (OGN) is currently considered Fairly Valued. The stock's GF Value™ is $14.55, compared to a current price of $13.48 — trading 7.4% below its estimated fair value. The current ROE % is 70.57%, which is 54% above median its 10-year median of 45.74 and 1103.2% above the Drug Manufacturers industry median of 5.87. Organon's overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Organon (OGN), the current ROE % is 70.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organon (OGN) Overvalued in 2026?
Based on GuruFocus' analysis, Organon stock appears to be undervalued.
The current stock price of $13.48 is trading 7.4% below its estimated GF Value™ of $14.55.
GuruFocus considers Organon to be Fairly Valued.
Key valuation signals for OGN:
ROE %: 70.57% (54% above median its 10-year median of 45.74)
GF Value™: $14.55 vs. price of $13.48 (7.4% below fair value)
Industry Position: 1103.2% above the Drug Manufacturers median (#53 of 936)
No single metric tells the full story. See the OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
73GF Score
Get the complete analysis for OGN
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OGN has been successfully added to your 
